Porównaj metody

	MSFC: Multiple Sclerosis Functional Composite	EDSS: Rozszerzona Skala Stanu Niepełnosprawności Kurtzke	RMI: Rivermead Mobility Index
Dziedzina	Neurologia	Neurologia	Neurologia
Rodzina	Process / pipeline	Process / pipeline	Process / pipeline
Rok powstania	1999	1983	1991
Twórca	Gary Cutter, Richard Rudick, and NMSS Consortium	John F. Kurtzke	Frank Collen, Derick Wade, and Rivermead Rehabilitation Centre
Typ	Clinician-administered performance test	Clinician-rated	Clinician-observed performance test
Źródło pierwotne	Cutter, G. R., Baier, M. L., Rudick, R. A., et al. (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Multiple Sclerosis, 5(4), 244-250.	Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444-1452.	Collen, F. M., Wade, D. T., Robb, G. F., Bradshaw, C. M. (1991). The Rivermead Mobility Index: A further development of the Rivermead Motor Assessment. International Disability Studies, 13(2), 50-54.
Inne nazwy	MS Functional Composite	Expanded Disability Status Scale	Rivermead Mobility Index
Pokrewne	4	4	5
Podsumowanie	The Multiple Sclerosis Functional Composite (MSFC) is an objective, performance-based assessment of MS-related disability capturing three key functional domains: lower extremity mobility, upper extremity coordination, and cognitive/processing speed. Developed in 1999 by the National MS Society and adopted widely in clinical trials, the MSFC provides quantifiable endpoints complementing the Expanded Disability Status Scale (EDSS). The three-component design addresses EDSS limitations by including cognition and standardizing measurement via timed tasks.	The EDSS is the most widely used clinical disability rating scale in multiple sclerosis research and practice. Developed by John Kurtzke in 1983, it provides a 0-10 ordinal scale capturing disease severity across eight neurological functional systems and functional status. The EDSS remains the primary endpoint in MS clinical trials and longitudinal cohort studies, with decades of prognostic and comparative data worldwide.	The Rivermead Mobility Index (RMI) is a brief, clinician-observed performance test of basic mobility abilities developed for assessing stroke and neurological rehabilitation outcomes. Published in 1991 by Frank Collen and colleagues at Rivermead Rehabilitation Centre (Oxford, UK), the 15-item index measures bed mobility, sitting/standing balance, transfers, and ambulation. The RMI is widely used in stroke units and rehabilitation settings to track functional recovery and predict discharge outcomes.